Article Text

PDF
Gene therapy with HGF cDNA in patients on peritoneal dialysis
  1. Y Maeda1,
  2. T Matsuoka2,
  3. K Matsuo2,
  4. Y Naiki2,
  5. M Sakaguchi3,
  6. H Hasegawa3
  1. 1
    Department of Hematology, Kinki University School of Medicine, Kinki University Sakai Hospital, Osaka, Japan
  2. 2
    Department of Nephrology, Kinki University School of Medicine, Kinki University Sakai Hospital, Osaka, Japan
  3. 3
    Kinki University Sakai Hospital, Osaka, Japan
  1. Dr Y Maeda, Department of Hematology, Kinki University School of Medicine, Osaka, Japan; ymaeda{at}med.kindai.ac.jp

Statistics from Altmetric.com

Continuous ambulatory peritoneal dialysis (CAPD) is an effective therapy for the treatment of patients with end-stage renal failure.1 Peritoneal fibrosis is one of the most common morphological changes observed in long-term CAPD patients and includes loss of mesothelial cells and severe accumulation of collagen fibres.2 The prevention of peritoneal fibrosis is necessary for maintenance of long-term CAPD. It has previously been reported that transforming growth factor-beta 1 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.